Merck and VivoSensMedical are evaluating new options for individualizing reproductive medicine

VivoSensMedical GmbH and Merck KGaA, a leading science and technology company, want to explore the potential for product development for the individualization of fertility therapies in a joint project.

Both companies want to identify algorithms as well as digital methods and products that can create new possibilities for reproductive medicine treatments, with the option of developing them together at a later date.

VivoSensMedical GmbH is a young medical technology company from Leipzig that developed OvulaRing with reproductive medicine specialist Prof. Henry Alexander. OvulaRing is a patented medical device that is approved throughout Europe to completely record the female cycle on the basis of high-resolution body core temperature measurement and to make statements on the individual cycle health based on this. With over 15.000 fully recorded cycles, the VivoSensMedical has the world's largest database of continuously measured body core temperatures.

Henry Alexander is one of the German pioneers in in vitro fertilization and has more than 40 years of experience in medical research and practice. “Slowly but surely, medicine is beginning to realize that therapy should be as individual as the person themselves. Every woman has an individual menstrual cycle pattern, which we can record with the help of OvulaRing’s vaginal ring sensors. I see great potential to consider these patterns in reproductive medicine treatments and to adapt them to the individual cycle biology.”

Source: Press release lifePR from March 10.03.2021th, XNUMX